TYRO3 and melanoma: Tyro3, Axl, and MerTK control myeloid-derived suppressor cell (MDSC) functionality, regulate MDSC-mediated immune suppression and augment anti-PD-1 therapy in melanoma patients (Holtzhausen et al., 2019), which highlights the role of these molecules in antitumor therapy.